Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: drkaz who wrote (12383)	11/4/2019 10:46:37 AM
From: KMBJN.	Read Replies (1) \| Respond to of 12873

Not only the 15% royalty to Theracour, but also they get to mark up the cost of manufacturing the drug (was it 30% already?). So, for round numbers sake - if it costs Theracour $1000 to make a dose, they charge NNVC $1300, and also take a 15% royalty on net sales. If NNVC can sell at $2000 per dose, Theracour gets a total of $600, or 30% of sales. Basically, they would be taking 60% of gross profits right off the top. Theracour has little incentive to keep costs down so NNVC can be profitable. Theracour Diwan wins and whatever is left for NNVC Diwan and NNVC shareholders will be less. The main incentive is that if NNVC fails, Theracour Diwan gets no $, so too much greed will kill the golden goose (if the goose really can lay golden eggs). Let's just see if NNVC can raise some money to get an IND and into trials without too much further dilution. Baby steps. It would be great if someone ask Diwan at ASM about costs of manufacturing drug, and whether the manufacturing process is all worked out yet. Some specifics about cost of manufacturing the drug and cost of a dose of VZVcide cream would be appreciated; i.e. if Theracour was the one selling the drug directly, what would be their gross margin? It would be good to ask Mr. Glick how giving Theracour 60% of gross profits is "a fair deal for NNVC shareholders."